Study Highlights Long-Term Success of Immunosuppressant-Free Islet Cell Therapy for Type 1 Diabetes

New long-term data published in The New England Journal of Medicine indicates the durability of a hypoimmune-modified islet cell therapy (UP421) for type 1 diabetes. The study shows these insulin-secreting cells can treat the condition effectively without requiring immunosuppressants. This represents a significant advancement, demonstrating safety, immune evasion, and sustained function over 14 months.